Lynx1 Capital Management Lp Buys 639,110 Shares of Neuphoria Therapeutics (NASDAQ:NEUP) Stock

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) major shareholder Lynx1 Capital Management Lp acquired 639,110 shares of the business’s stock in a transaction dated Tuesday, October 21st. The stock was purchased at an average cost of $5.14 per share, for a total transaction of $3,285,025.40. Following the transaction, the insider owned 875,328 shares in the company, valued at approximately $4,499,185.92. The trade was a 270.56% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Neuphoria Therapeutics Stock Up 54.1%

Shares of Neuphoria Therapeutics stock opened at $6.24 on Friday. The firm’s 50 day moving average price is $12.15 and its 200-day moving average price is $8.46. Neuphoria Therapeutics Inc. has a 52-week low of $2.12 and a 52-week high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings data on Monday, September 29th. The company reported ($5.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($5.23). The firm had revenue of ($0.01) million for the quarter. On average, equities research analysts forecast that Neuphoria Therapeutics Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on NEUP shares. Weiss Ratings downgraded shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Neuphoria Therapeutics in a research report on Tuesday, August 26th. Maxim Group upped their price objective on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, September 11th. Finally, Wall Street Zen raised shares of Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 26th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Neuphoria Therapeutics presently has a consensus rating of “Hold” and an average price target of $28.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.